Clinical Trials

HCA Midwest Health currently has 24 clinical cancer trials available. Our clinical research program looks at new ways to prevent, detect, or treat disease.

Important information


CDC guidance now recommends that moderately to severely immunocompromised patients receive an additional (third) dose of an mRNA COVID-19 vaccine (Pfizer-BioNTech or Moderna). If you have undergone anti-cancer therapy in the past year, you are within 1 year of stem cell transplantation or are receiving medications that suppress your immune system, you are encouraged to obtain a third COVID-19 vaccination shot. If you received the Johnson & Johnson single dose vaccination, please consult your doctor regarding next steps. Find vaccination locations here.

If you are within 100 days of a stem cell transplantation, we do not recommend that you receive a COVID-19 vaccination until you are cleared by your care team to do so. If you are currently on a clinical research trial, please contact your clinical research team for more guidance. Please contact your care coordinator if you have additional questions about receiving an additional COVID-19 vaccine shot.

The HCA Midwest Health clinical research program supports overall patient care by offering another therapeutic option through clinical trials. These clinical studies are available through HCA Midwest Health and various pharmaceutical and CRO partners.

AML 58: Tamibarotene in Combination with Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who Are Ineligible for Standard Induction Therapy. PI: Suman Kambhampati, MD
Facility: Research Medical Center


AML 64: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy. PI: Suman Kambhampati, MD
Facility: Research Medical Center


CLL 51: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-322). PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center


MM 136: A Phase 3, two-stage, randomized, multicenter, open label study comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) vs Daratumumab, Bortezomib and Dexamethasone (DVD) in subjects with relapsed or refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM). PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center


MM-001:

A Phase 1/2a Study of Modakafusp alfa in combination with Daratumumab Subcutaneous (SC) (Moda + Dara) in patients with relapsed or refractory Multiple Myeloma. PI: Suman Kambhampati, MD


Facility: Research Medical Center


MM-002:

A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Treatment after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM). PI: Suman Kambhampati, MD


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

KC-BRE-002: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib. PI: Aruna Rokkam, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

Catalyst:

Evaluates the safety and effectiveness of the Amulet LAA Occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. Principal Investigator: Dr. James Marcum


Facility: Overland Park Regional Medical Center, Research Medical Center


Champion AF:

To determine if left atrial appendage closure with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation. Principal Investigator: Dr. Dhanunjaya Lakkireddy


Facility: Overland Park Regional Medical Center, Research Medical Center


Define AF:

Aims to improve the understanding of how data from the Reveal LINQ™ or LINQ II™ insertable cardiac monitor (ICM) can be used to guide the management of Afib. Principal Investigator: Dr. Dhanunjaya Lakkireddy


Facility: Centerpoint, Research Medical Center, Overland Park Regional Medical Center, Menorah Medical Center


Leadless II:

Designed to confirm the safety and effectiveness of the Aveir LP System in a subject population indicated for a single chamber pacemaker. Principle Investigator: Dr. Dhanunjaya Lakkireddy


Facility: Overland Park Regional Medical Center


LUX-Dx PERFORM:

To characterize the utilization of the remote programming feature of the Boston Scientific (BSC) Insertable Cardiac Monitor (ICM) device. The study will also collect data to characterize the performance of arrhythmia detection. Finally, data collected will be used to analyze and characterize the ICM system-related safety events. Principal Investigator: Dr. Scott Koerber


Facility: Centerpoint, Research Medical Center, Overland Park Regional Medical Center


RELIEVE-HF:

To provide reasonable assurance of safety and effectiveness of the V-Wave Interatrial Shunt System to improve clinical outcomes in a certain high-risk subset of symptomatic patients suffering from HF. Principal Investigator: Dr. Dhanunjaya Lakkireddy


Facility: Overland Park Regional Medical Center, Research Medical Center


Solve CRT:

To study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Therapy. Principal Investigator: Dr. Dhanunjaya Lakkireddy


Facility: Overland Park Regional Medical Center, Research Medical Center

KC-GI-001: A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT). PI: Mohammad Mozayen, MB
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

There are currently no research trials.

GYN-001: A Phase 2 Open label, Multicenter study to evaluate efficacy and safety of ZN-C3 in adult women with recurrent or persistent uterine serous carcinoma. PI: K. Shawn Lybarger, DO
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center


GYN-003: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Investigator’s Choice in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer. PI: K. Shawn Lybarger, DO
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center


GYN-004: A Phase 3, Randomized, Placebo-Controlled, Double-Blind multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 Wild-Ty[e, advanced or recurrent endometrial carcinoma. PI: K. Shawn Lybarger, DO
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center


GYN-005: A Phase 1B22 Baseky study of ACR-368 as monotherapy and in combiinatio with Gemcitabien in Adults with platinum-resistant ovarian carcinoma, Endometrial Adenocarcinoma and Urothelial carcinoma based on Acrivon Oncosignature status. PI: K. Shawn Lybarger, DO
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

There are currently no research trials.

KC-CNS-001: A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma. PI: Amandeep Kalra, MD
Facility: Research Medical Center


KC-CNS-002: A Parallel-group, Two-staged, Phase 2/3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants with progressive NF2 mutated Meningiomas. PI: Amandeep Kalra, MD
Facility: Research Medical Center

KC-LUN-004: A Radomized, double-blind international multicenter Phase III study to evaluate the anti-tumor efficacy and safte of HLX10 or placebo in combo with chemo (carbo/sisplatin Etoposide) and concurrent radiotherapy in patients with Limited-stage (3 or less) Small Cell Lung Cancer (LS-SCLC). PI: Joseph Stilwill, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center


LUN-002: A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies. PI: Joseph Stilwill, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center


LUN-003: A Randomized, open-label study of HLX10 plus chemo (carbo-Etoposide) in comparision with Atezolizumab pluse chemo in Previously untreated US patient with extensive Stage (4) Small Cell Lung Cancer (ES-SCLC). PI: Joseph Stilwill, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

There are currently no research trials.